Julien Soubrier

Julien Soubrier

Auto-generated profile, based on publicly available information

Julien Soubrier

Technology Advancement Unit Genetics and Molecular Pathology, SA Pathology Adelaide South Australia Australia

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in Science Advances
Verified
Journal Article
Open access
PDF file
Bastien LlamasBastien Llamas
Bastien Llamas
LFLars Fehren-Schmitz
Lars Fehren-Schmitz
GVGuido Valverde
Guido Valverde
JSJulien Soubrier
Julien Soubrier
SMSwapan Mallick
Swapan Mallick
WHWolfgang Haak
Wolfgang Haak
Native American population history is reexamined using a large data set of pre-Columbian mitochondrial genomes.

5 April 2024 in Australian and New Zealand Journal of Obstetrics and Gynaecology
Verified
Journal Article
Open access
ARAlice Rogers
Alice Rogers
LJLucas De Jong
Lucas De Jong
WWWendy Waters
Wendy Waters
LRLesley H. Rawlings
Lesley H. Rawlings
KSKeryn Simons
Keryn Simons
KKKarin Kassahn
Karin Kassahn
Background: Trio exome sequencing can be used to investigate congenital abnormalities identified on pregnancy ultrasound, but its use in an Australian context has not been assessed.Aims: Assess clinical outcomes and changes in management after expedited genomic testing in the prenatal period to guide the development of a model for widespread implementation.Materials and methods: Forty‐three prospective referrals for whole exome sequencing, including 40 trios (parents and pregnancy), two singletons and one duo were assessed in a tertiary hospital setting with access to a state‐wide pathology laboratory. Diagnostic yield, turn‐around time (TAT), gestational age at reporting, pregnancy outcome, change in management and future pregnancy status were assessed for each family.Results: A clinically significant genomic diagnosis was made in 15/43 pregnancies (35%), with an average TAT of 12 days. Gestational age at time of report ranged from 16 + 5 to 31 + 6 weeks (median 21 + 3 weeks). Molecular diagnoses included neuromuscular and skeletal disorders, RASopathies and a range of other rare Mendelian disorders. The majority of families actively used the results in pregnancy decision making as well as in management of future pregnancies.Conclusions: Rapid second trimester prenatal genomic testing can be successfully delivered to investigate structural abnormalities in pregnancy, providing crucial guidance for current and future pregnancy management. The time‐sensitive nature of this testing requires close laboratory and clinical collaboration to ensure appropriate referral and result communication. We found the establishment of a prenatal coordinator role and dedicated reporting team to be important facilitators. We propose this as a model for genomic testing in other prenatal services.